Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

FDA Advisory Committee to review Amgen’s biosimilar AmAb candidate

Jun 13, 2016

Amgen announces FDA Advisory Committee Meeting to review ABP 501 (biosimilar adalimumab).  FDA has set a Biosimilar User Fee target action date of 25 September 2016.